Clinical Research Directory

Dietary Fibre Supplementation to Delay Disease Progression in Early Prostate Cancer

This qualitative research study, based on semi-structured interviews and a focus group, aims to explore the attitudes of prostate cancer patients on active surveillance (AS) towards dietary fibre supplementation, given the potential benefits demonstrated in previous research. Prostate cancer patients on AS, often overlooked in the literature, experience cyclical anxiety, particularly regarding disease progression. Lifestyle modifications, including dietary changes, are pursued by a number of these patients as a preventative measure. Dietary fibre such as inulin and psyllium have promising results in studies of pelvic cancers. However, it is important to note that these findings do not directly apply to patients who are currently undergoing AS for prostate cancer. Despite potential side effects, these dietary fibres may contribute to anti-inflammatory and antitumorigenic effects. Building on this evidence, we aim to explore patient perspectives on the feasibility and acceptability of dietary fibre supplementation during AS. The insights gained will guide the development of a feasibility and/or pilot studies and, subsequently, a multicentre randomised controlled trial. If successful, this intervention could potentially reshape clinical practice for patients with prostate cancer on AS.

Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

To learn if belzutifan can help to control the disease in patients with metastatic RCC who are considered candidates for active surveillance and have not undergone previous systemic treatment. The safety of belzutifan in this patient population will also be studied.

Personalized Care Pathways for Bowel Symptoms in Rectal Cancer Patients_contributing Factors (Treatable)

Colorectal cancer is the 2nd and 3rd most common cancer in respectively women and men, of which about 40% is located in the rectum. The gold standard treatment for rectal cancer (RC) is a low anterior resection combined with chemoradiotherapy. However, this treatment negatively affects various aspects of bowel function and patients' quality of life. These bowel symptoms often remain prevalent, even 12 months after RC treatment. The aim of this study is to identify the factors contributing to persistent bowel symptoms and their long-term impact on quality of life following treatment for rectal cancer, assessed 12 months after surgery or stoma closure in surgically treated patients, and 12 months after completion of neoadjuvant therapy in patients managed with active surveillance/watch-and-wait. These insights are crucial for developing an effective care approach, as they help determine when specific evaluations should be conducted and which treatments should be applied at different stages.

Active Surveillance for Limited GGNs

This study is a single-arm, multi-center, phase III trial conducted under the Eastern Cooperative Thoracic Oncoloy Project (ECTOP) . The primary objective of the study is to assess the 5-year overall survival of patients with one or two ground-glass opacities by employing an active surveillance approach rather than immediate surgical resection.

Surveillance for Multifocal GGNs

This study is a single-arm, multi-center, phase III trial conducted under the Eastern Cooperative Thoracic Oncoloy Project (ECTOP) with the identification number ECTOP-1021. The primary objective of the study is to assess the overall survival of patients with multifocal ground-glass opacities by employing a active surveillance approach rather than opting for surgical resection.

Statistical Analysis Plan for the SANO-trial: Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Active Surveillance for Oesophageal Cancer

An active surveillance approach is proposed after completion of neoadjuvant chemoradiotherapy (nCRT) for carcinoma of the oesophagus. In this SANO (i.e. Surgery As Needed for Oesophageal cancer) approach, surgical resection is offered only to patients in whom a locoregional regrowth is highly suspected or proven, without distant dissemination. Such an organ-preserving strategy can have great advantages, but is only justified if long-term survival is non-inferior to that of the current standard trimodality approach comprising neoadjuvant chemoradiotherapy followed by standard surgery. The aim of this study is to assess the (cost-)effectiveness (including non-financial costs and survival) of active surveillance for patients with squamous cell- or adenocarcinoma of the oesophagus or oesophago-gastric junction.